Australian healthcare company Stirling Products Limited...

Australian healthcare company Stirling Products Limited (ASX:STI) advises that the
Company’s first shipment of bulk botanical product arrived in Canada overnight and
is now awaiting Bond clearance.
Establishing export arrangements for the export of finished botanical products in
bulk with the Ukraine has proven to be a significant exercise.
Livingston International, a leading North American provider of global customs and
freight services, has been appointed as the Company’s freight and logistics agent.
Under their direction and with the support of a number of industry experts, the
Company has now successfully established the protocol for all future exports to be
seamlessly processed.
Following Customs clearance, the bulk imported products will be shipped to Qpharm
Inc who has been contracted to complete the Company’s compliance bottling and
packaging in readiness for sale in the North American markets.
Following receipt of today’s delivery all final compliance and packaging design work
will now be completed. The Company will then have sufficient initial inventory to
support gross sales of its first four lead products (including ImunoXel) of over US
800,000 in the first few months of the forthcoming network marketing initiative
announced last week.
For further information see www.stirlingproducts.net or contact:
Peter Boonen
Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E: [email protected]
For all Investor Relations inquiries please contact:
James Moses
Mandate Corporate
Ph: +61 420 991 574
E: [email protected]